Grifols And Japanese Red Cross Sign Blood Screening Deal


News: Spanish drugmaker Grifols has signed a US$375mn deal with Japan's Red Cross Society (JRC) to conduct blood analysis for the humanitarian organisation over the next seven years, reports Reuters. Under the terms of the deal, the company will conduct nucleic acid screening of the country's 5.3mn annual blood transfusions. Grifols will provide the JRC with its newest automation platform - the Procleix Panther System - and associated assays, which will be used to screen blood donations for HIV and hepatitis viruses prior to their release for medical use.

This article is tagged to:
Related sectors of this article: Pharmaceuticals & Healthcare, Agreements - Pharmaceuticals
Geography: Spain